

Full Speed Ahead

to Personalized Medicine.

August 2022 | NASDAQ:IPA



IPAA

ENGINEERED for the biotherapeutic RACE

At-A-Glance

Corporate profile



IPA is an innovative, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score for its antibody service portfolio.¹

We own a proprietary set of highly specialized technologies used to customize the successful discovery of complex and novel therapies along every step of the development process.

Our services are supported with advanced omics and complex intelligence technology, providing unparalleled accuracy in personalized medicine.

Capital Structure (all values in CAD unless otherwise noted) (NASDAQ: IPA); (TSXV: IPA)

SHARES DATA, 2021 (as of July 31, 2022)

Shares Outstanding	24,836,723
Share Price (CAD)	\$5.29
Market Cap	\$131,386,265

BALANCES (as of April 30, 2022)

Cash on Hand	\$29,964,898
--------------	--------------

WARRANTS (as of April 30, 2022)

Balance	Weighted Average Exercise Price	Weighted Average Life Remaining (Years)	Future Cash Opportunity
130,111 ⁽¹⁾	\$16.81	3.77	\$2,187,166

(1) Price and cash value stated in USD

OPTIONS (as of April 30, 2022)

	Balance	Weighted Average Exercise Price	Weighted Average Life Remaining (Years)
Exercisable	1,094,296	\$7.64	2.16
Unvested	529,854	\$9.63	4.35
Total	1,624,150	\$8.29	2.88

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035; p.118


IPA – Twelve Month Selected Highlights

Milestones and Achievements in a Year



- **RANKED #1** global CRO in leading market analysis¹
- **ACQUIRED BioStrand** with disruptive multi-omic analysis software, IP for universal omic language patterns
 - * **Universal fingerprints** to enable the selection of any biologic sequence based on activity
 - * **Patent-pending technology** aimed at disrupting multiple industries (therapeutic discovery, healthcare, AI, quantum computing, agriculture, etc).
- **Eurofins Discovery** signs service and marketing collaboration
- **Pierre Fabre** partners for multi-target antibody discovery research collaboration in oncology
- **ONLY REMAINING** efficacious 1st generation therapy against all tested variants of concern
- **DOD** supported program with **Elektrofi** for pandemic preparedness

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035; p.118



Known for robust technologies with clinically relevant outcomes

- Exceptional diversity of candidates
- Sequences associated with FUNCTION
- Leading custom B-Cell platforms and Deep Phage technologies
- Workflow efficiency and speed [powered by LENS^{ai}[™]]
- Fast growing - over 600 clients, 80% of top 20 pharma

Integrated End-to-End Technologies




Global Players and Partners

Chosen and respected by
industry leaders and titans



Reliable and Robust Growth





The Problem

Matching the mutation to
the therapy



The Problem - Too Much Data

Too complex to decode at increasing volumes

Genomics research is predicted to generate:

40 exabytes of data
in the next decade¹



1. <https://www.genome.gov/about-genomics/fact-sheets/Genomic-Data-Science>

- Genomic data science enables access to huge amounts of biological data
- Ability to analyze / use data limited
- Sequencing capability far outpaces ability to decipher, gap is widening

The Opportunity

Solve the efficiency paradox for pharmaceuticals




Complexity of protein adds additional challenges, standard AI programming not effective:

- mAbs drug discovery is a complex combinatorial challenge
- $\sim 20^{62}$ mAbCDR variants exceeds $\sim 10^{80}$ atoms in the universe

Protein complexity makes standard AI programming extremely difficult:


Small Molecule:

Aspirin
-21 Atoms



Protein Therapeutics:

Monoclonal Antibodies
-25,000 Atoms




LENS^{ai}™ Complex Intelligence Technology

Integrative solution



50-1000x faster ▶

- Indexed with coded universal fingerprints (HYFTS) for harvesting immediate data on any topic
- Instantly retrieves information on the activity of any sequence
 - Enables in silico approach for novel discoveries in many fields, based on **Universal Fingerprints**.
 - **Fingerprints** are coded and indexed as primary tool in software, removing unnecessary search of irrelevant sequences and structures that are not linked to biological activity.
- Complex data becomes specific and applicable — instantly
- Rapid exploration, interrogation, and correlation of new and existing data or omics
- Optimal data structure to leverage more complex AI models - on more (disperse) data



LENS^{ai} Powered by HYFTs™

Industry disruptive efficiency for personalized drug discovery



The Difference

HYFTs universal fingerprints organize the biosphere

- Built-in biological language coded and index in software
- HYFT patterns represented in DNA, RNA and AA.

Multi-layers of function, structure, position, etc. creates a multilevel intelligence network

The Genius

Our universal fingerprints are data objects


- Dr. Van Hyfte isolated 660 million data objects that effectively order the biosphere.
- Each HYFT carries layers of information, metadata that can be continuously added.

660 million indexed data objects



- DNA, RNA, AA representation
- Strictness in the sequence order and arrangement outside of fingerprint
- position, function, structure
- cell type
- species
- pathogenicity
- pathway or action
- ... and more

AI Drug Discovery Companies*



*Release Date March 3,2022 Frost & Sullivan

The Goal

A new standard for personalized medicine

IPA's technology using *universal fingerprints* disrupts the pharmaceutical and software industries.

LENS^{ai} can build safe and personalized medicines faster, by rapidly identifying the exact source of a disease (mutation) and novel therapies.

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements, including future-oriented financial information (“FOFI”). Forward-looking statements can generally be identified by the use of language such as “may”, “expect”, “estimate”, “anticipate”, “intend”, “believe”, “potential” & “continue” or the negative thereof or similar variations. Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation. The Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, & anticipated events & circumstances may affect the ultimate financial results. Projections are inherently subject to substantial & numerous uncertainties & to a wide variety of significant business, economic & competitive risks, & the assumptions underlying the projections may be inaccurate in any material respect, including, but not limited to, those risks set forth in the Company’s Management Discussion & Analysis for the year ended April 30, 2021, a copy of which may be obtained from SEDAR.com. The purpose of FOFI provided in this presentation is to provide prospective investors with information pertaining to the Company’s long-term business objectives. Readers are cautioned that this information may not be appropriate for other purposes.



IPA

Thank you!

ENGINEERED for the biotherapeutic RACE